Nirmatrelvir-Ritonavir Does Not Prevent People Exposed To COVID-Infected Household Members From Getting Infected With Virus, Study Finds

MedPage Today (7/17, Kahn) reports, “Nirmatrelvir-ritonavir (Paxlovid) did not prevent people exposed to COVID-infected household members from getting infected with the virus, according to the final results of the phase II/III EPIC-PEP study.” The research found that “across more than 2,700 exposed adults in the trial, symptomatic confirmed infections at 14 days occurred in 2.6% of those taking a 5-day course of the antiviral medication, 2.4% of those receiving a 10-day course, and 3.9% of the placebo recipients.” However, “neither of those differences versus the placebo group were statistically significant.” The findings were published in the New England Journal of Medicine.